Literature DB >> 3403939

Nosocomial respiratory tract colonization and infection with aminoglycoside-resistant Acinetobacter calcoaceticus var anitratus: epidemiologic characteristics and clinical significance.

J E Peacock1, L Sorrell, F D Sottile, L E Price, W A Rutala.   

Abstract

During the period July 1983 through December 1984, aminoglycoside-resistant Acinetobacter calcoaceticus var anitratus (ACA) were isolated from 98 patients in a university hospital. Eighty-seven percent of patients (85/98) acquired aminoglycoside-resistant ACA in the intensive care unit (ICU) and 92% (90/98) of all initial isolates were from sputum. ICU patients with respiratory colonization/infection with aminoglycoside-resistant ACA were compared with matched ICU controls with other gram-negative rods in sputum. Compared with controls, the duration of ICU stay prior to colonization/infection with aminoglycoside-resistant ACA was significantly longer for cases (14.7 days v 5.9 days, P = 0.002). Although exposures to devices and procedures were not significantly different for the two groups, cases received respiratory therapy significantly longer than did controls (14.7 days v 6.6 days, P = 0.006). Prior to isolation of aminoglycoside-resistant ACA in sputum, cases received more cephalosporins than did controls (1.9 v 1.2, P = 0.018); aminoglycoside usage in the two groups was comparable but cases tended to have received aminoglycoside for longer durations before colonization/infection than had controls (9.0 days v 6.1 days, P = 0.08). Following sputum isolation of ACA, 6 of 22 cases developed ACA bacteremia compared with bacteremia in 2 of 22 controls. We conclude that factors predisposing to colonization/infection with aminoglycoside-resistant ACA were extended ICU care, prolonged respiratory therapy, and prior therapy with cephalosporins and aminoglycoside. In addition, ACA may be a more common cause of secondary bacteremia than previously appreciated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3403939     DOI: 10.1086/645859

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  7 in total

Review 1.  Acinetobacter pneumonia: a review.

Authors:  Joshua D Hartzell; Andrew S Kim; Mark G Kortepeter; Kimberly A Moran
Journal:  MedGenMed       Date:  2007-07-05

Review 2.  Acinetobacter species as nosocomial pathogens.

Authors:  D H Forster; F D Daschner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-02       Impact factor: 3.267

Review 3.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

4.  Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain.

Authors:  S López-Hernández; T Alarcón; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

5.  Emergence of resistant isolates of Acinetobacter calcoaceticus- A. baumannii complex in a Spanish hospital over a five-year period.

Authors:  M I García-Arata; T Alarcón; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

6.  Risk factors and outcomes for patients with bloodstream infection due to Acinetobacter baumannii-calcoaceticus complex.

Authors:  Teena Chopra; Dror Marchaim; Paul C Johnson; Reda A Awali; Hardik Doshi; Indu Chalana; Naomi Davis; Jing J Zhao; Jason M Pogue; Sapna Parmar; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

Review 7.  Infection Control Programs and Antibiotic Control Programs to Limit Transmission of Multi-Drug Resistant Acinetobacter baumannii Infections: Evolution of Old Problems and New Challenges for Institutes.

Authors:  Chang-Hua Chen; Li-Chen Lin; Yu-Jun Chang; Yu-Min Chen; Chin-Yen Chang; Chieh-Chen Huang
Journal:  Int J Environ Res Public Health       Date:  2015-07-30       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.